Ceramide as a Target of Marine Triterpene Glycosides for Treatment of Human Myeloid Leukemia
AbstractAcute myeloid leukemia (AML) is a heterogeneous myeloid clonal disorder exhibiting the accumulation of immature myeloid progenitors in the bone marrow and peripheral blood. Standard AML therapy requires intensive combination chemotherapy, which leads to significant treatment-related toxicity. The search for new, low toxic marine agents, inducing the generation of ceramide in leukemic cells is a new approach to improve the therapy of leukemia. This review focuses on the metabolism of sphingolipids, the role of ceramide in treating leukemia, and the antitumor activity, related to ceramide metabolism, of some marine metabolites, particularly stichoposides, triterpene glycosides extracted from sea cucumbers of the family Stichopodiidae. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Yun, S.-H.; Shin, S.-W.; Stonik, V.A.; Park, J.-I. Ceramide as a Target of Marine Triterpene Glycosides for Treatment of Human Myeloid Leukemia. Mar. Drugs 2016, 14, 205.
Yun S-H, Shin S-W, Stonik VA, Park J-I. Ceramide as a Target of Marine Triterpene Glycosides for Treatment of Human Myeloid Leukemia. Marine Drugs. 2016; 14(11):205.Chicago/Turabian Style
Yun, Seong-Hoon; Shin, Sung-Won; Stonik, Valentin A.; Park, Joo-In. 2016. "Ceramide as a Target of Marine Triterpene Glycosides for Treatment of Human Myeloid Leukemia." Mar. Drugs 14, no. 11: 205.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.